Terms: = Lymphoma AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E AND Diagnosis
293 results:
1. [Bone marrow histology of cytopenias : Contribution to hematological differential diagnosis].
Kreipe H
Pathologie (Heidelb); 2024 Mar; 45(2):148-158. PubMed ID: 38381371
[TBL] [Abstract] [Full Text] [Related]
2. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy.
Campillo-Marcos I; Casado-Pelaez M; Davalos V; Ferrer G; Mata C; Mereu E; Roué G; Valcárcel D; Molero A; Zamora L; Xicoy B; Palomo L; Acha P; Manzanares A; Tobiasson M; Hellström-Lindberg E; Solé F; Esteller M
Cancer Res Commun; 2024 Feb; 4(2):365-377. PubMed ID: 38300528
[TBL] [Abstract] [Full Text] [Related]
3. Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Nabergoj M; Eikema DJ; Koster L; Platzbecker U; Sockel K; Finke J; Kröger N; Forcade E; Nagler A; Eder M; Tischer J; Broers AEC; Kuball J; Wilson KMO; Hunault-Berger M; Collin M; Russo D; Corral LL; Helbig G; Mussetti A; Scheid C; Gurnari C; Raj K; Drozd-Sokolowska J; Yakoub-Agha I; Robin M; McLornan DP
Bone Marrow Transplant; 2024 Mar; 59(3):395-402. PubMed ID: 38195984
[TBL] [Abstract] [Full Text] [Related]
4. When to use which molecular prognostic scoring system in the management of patients with mds?
Kewan T; Bewersdorf JP; Gurnari C; Xie Z; Stahl M; Zeidan AM
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101517. PubMed ID: 38092484
[TBL] [Abstract] [Full Text] [Related]
5. CDC-NET: a cell detection and confirmation network of bone marrow aspirate images for the aided diagnosis of AML.
Su J; Liu Y; Zhang J; Han J; Song J
Med Biol Eng Comput; 2024 Feb; 62(2):575-589. PubMed ID: 37953336
[TBL] [Abstract] [Full Text] [Related]
6. CD72 is a pan-tumor antigen associated to pediatric acute leukemia.
Buldini B; Faggin G; Porcù E; Scarparo P; Polato K; Tregnago C; Varotto E; Rizzardi P; Rizzari C; Locatelli F; Biffi A; Pigazzi M
Cytometry A; 2023 Dec; 103(12):1004-1009. PubMed ID: 37876342
[TBL] [Abstract] [Full Text] [Related]
7. Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (mds) in United States community practices.
Egloff SA; Cao X; Lachs R; Martin C; Mattlin M; Fennell E; Rayburn D; Schlauch D; Kurbegov D; Ide S; Battiwalla M
Leuk Lymphoma; 2023 Dec; 64(13):2101-2112. PubMed ID: 37680012
[TBL] [Abstract] [Full Text] [Related]
8. A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (mds).
Sabile JMG; Kaempf A; Tomic K; Manu GP; Swords R; Migdady Y
Leuk Lymphoma; 2023 Oct; 64(10):1689-1694. PubMed ID: 37440338
[TBL] [Abstract] [Full Text] [Related]
9. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation.
Yalniz FF; Greenbaum U; Pasvolsky O; Milton DR; Kanagal-Shamanna R; Ramdial J; Srour S; Mehta R; Alousi A; Popat UR; Nieto Y; Kebriaei P; Al-Atrash G; Oran B; Hosing C; Ahmed S; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
Transplant Cell Ther; 2024 Feb; 30(2):205.e1-205.e12. PubMed ID: 37437764
[TBL] [Abstract] [Full Text] [Related]
10. Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation.
Saleh K; Arbab A; Ghez D; Bigenwald C; Cotteret S; Marzac C; Pasquier F; Pilorge S; Saada V; Vergé V; Ribrag V; Castilla-Llorente C
Immunotherapy; 2023 Apr; 15(6):401-407. PubMed ID: 36950962
[TBL] [Abstract] [Full Text] [Related]
11. Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes.
Tinsley-Vance SM; Ali NA; Ball S; Aguirre LE; Jain AG; Hussaini MO; Chan O; Kuykendall A; Sweet K; Lancet J; Padron E; Sallman DA; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):355-359. PubMed ID: 36813626
[TBL] [Abstract] [Full Text] [Related]
12. Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders.
Mikulska M; Testi D; Russo C; Balletto E; Sepulcri C; Bussini L; Dentone C; Magne F; Policarpo S; Campoli C; Miselli F; Cilli A; Ghiggi C; Aquino S; Di Grazia C; Giannella M; Giacobbe DR; Vena A; Raiola AM; Bonifazi F; Zinzani P; Cavo M; Lemoli R; Angelucci E; Viale P; Bassetti M; Bartoletti M
Br J Haematol; 2023 May; 201(4):628-639. PubMed ID: 36806152
[TBL] [Abstract] [Full Text] [Related]
13. SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes.
Volpe VO; Garcia-Manero G; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):168-177. PubMed ID: 36682988
[TBL] [Abstract] [Full Text] [Related]
14. Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice.
Montoro MJ; Pomares H; Coll R; Bernal Del Castillo T; Tormo M; Jiménez A; Brunet S; Casaño J; Oiartzabal I; Díez-Campelo M; Ramos F; Romero R; Salido-Fiérrez E; Pedro C; Bargay J; Muñoz-Novas C; López R; Rafel M; Valcárcel D;
Leuk Lymphoma; 2023 Mar; 64(3):679-690. PubMed ID: 36577016
[TBL] [Abstract] [Full Text] [Related]
15. Red Blood Cell Deformability and Distribution Width in Patients with Hematologic Neoplasms.
Lee JM; Suh JS; Kim YK
Clin Lab; 2022 Oct; 68(10):. PubMed ID: 36250843
[TBL] [Abstract] [Full Text] [Related]
16. Genomic Landscape of Mixed-Phenotype Acute Leukemia.
Hennawi M; Pakasticali N; Tashkandi H; Hussaini M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232559
[TBL] [Abstract] [Full Text] [Related]
17. A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the mds-CAN registry.
Buckstein R; Chodirker L; Mozessohn L; Yee KWL; Geddes M; Zhu N; Shamy A; Leitch HA; Christou G; Banerji V; Brian L; Khalaf D; St-Hilaire E; Finn N; Nevill T; Keating MM; Storring J; Delage R; Parmentier A; Thambipillai A; Siddiqui M; Westcott C; Cameron C; Mamedov A; Spin P; Tang D
Leuk Lymphoma; 2022 Dec; 63(13):3165-3174. PubMed ID: 36095125
[TBL] [Abstract] [Full Text] [Related]
18. Whole-genome sequencing as an alternative to analyze copy number abnormalities in acute myeloid leukemia and myelodysplastic syndrome.
Lyu X; Li T; Zhu D; Cheng Y; Chen Y; He X; Li Z; Li S; Wu W; Geng S; Zhang M; Yao C; Li J; Li Y; Chang Y; Li Y; Zhu Z; Mao M; Song Y
Leuk Lymphoma; 2022 Oct; 63(10):2301-2310. PubMed ID: 35695096
[TBL] [Abstract] [Full Text] [Related]
19. Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes.
Zeidan AM; Joshi N; Kale H; Wang WJ; Corman S; Salimi T; Epstein RS
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):670-679. PubMed ID: 35614009
[TBL] [Abstract] [Full Text] [Related]
20. De Novo myelodysplastic syndromes in patients 20-50 years old are enriched for adverse risk features.
Epstein-Peterson ZD; Spitzer B; Derkach A; Arango JE; McCarter JGW; Medina-Martínez JS; McGovern E; Farnoud NR; Levine RL; Tallman MS
Leuk Res; 2022 Jun; 117():106857. PubMed ID: 35598475
[TBL] [Abstract] [Full Text] [Related]
[Next]
